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recognised protection by VZIG, and sub-clinical infection.
Study designs and other criteria for inclusion in the review
It was not stated whether a systematic review of the literature had been undertaken to identify relevant studies. No information on the designs and characteristics of the primary studies was provided.
Sources searched to identify primary studies
Not stated.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
Five primary studies provided the clinical evidence.
Methods of combining primary studies
A narrative method appears to have been used to combine the primary estimates.
Investigation of differences between primary studies
Not stated. 
Results of the review

Methods used to derive estimates of effectiveness
Some assumptions based on experts' opinions were made.
Estimates of effectiveness and key assumptions
The probability of recognising exposure to varicella was 0.8 (range: 0.7 -0.95). The probability of receiving VZIG once exposed was 0.9 (range: 0.50 -0.95).
Measure of benefits used in the economic analysis
The model outputs were the probability of receiving VZIG, the probability of infection, and the probability of hospitalisation for acyclovir treatment with the immunisation and non-immunisation strategies.
Direct costs
The time horizon of the study was unclear, but the authors applied an annual discount rate of 5% to costs incurred after the second year. The unit costs were not reported separately from the quantities of resources used as the costs were presented as macro-categories (cost per episode of treatment). The health services included in the economic evaluation were immunisation, VZIG treatment and hospital admission for acyclovir treatment. The authors stated that all the direct costs were included in the analysis. For example, the cost of immunisation included the costs of two doses of vaccine, a visit and vaccine administration. The cost/resource boundary of the study was not stated, but it could have been that of the hospital. The resource use data were estimated on the basis of published evidence and experts' opinions. The costs came from hospital databases. The price year was not reported.
Statistical analysis of costs
The costs were treated deterministically.
Indirect Costs
The indirect costs were not considered.
Currency
US dollars ($).
Sensitivity analysis
Univariate and multivariate sensitivity analyses were performed to examine the robustness of the estimated costs to variations in the model inputs. A worst-case scenario was also considered, where model assumptions were chosen to limit the cost-effectiveness of vaccination. The ranges of values used in the analysis were derived from the literature and from experts' opinions.
Estimated benefits used in the economic analysis
The probability of receiving VZIG was 0% with immunisation and 64.8% with non-immunisation. The probability of infection was 2.8% with immunisation and 45% with non-immunisation.
The probability of hospitalisation for acyclovir treatment was 2.2% with immunisation and 42.3%% with nonimmunisation.
Cost results
The estimated costs per patient were $250 with immunisation and $2,700 with non-immunisation.
The cost of vaccination in the immunisation strategy was totally offset by the avoided hospital admissions.
The sensitivity analysis showed that immunisation remained the dominant strategy under all scenarios examined. Only the magnitude of the cost-savings changed. In particular, when the cost of hospitalisation rose, the rate of exposure to varicella increased, as did the rate of protection from vaccination and the cost-savings rose. When the cost of vaccination increased, the number of patients receiving VZIG increased and the efficacy of VZIG improved, then the cost-savings fell. Even in the worst-case scenario (multivariate analysis with all the worst values for vaccination), immunisation remained cost-saving compared with non-immunisation ($300 versus $588, respectively).
